Icu Medical Inc/De (NASDAQ: ICUI)

ICU Medical Inc., a company with the ticker symbol ICUI, is a prominent player in the medical device industry, specializing in the development, manufacturing, and sale of innovative medical products used in infusion therapy, vascular access, and vital care applications.

The company's operations are divided into three main segments: Consumables, Infusion Systems, and Vital Care. The Consumables segment includes a variety of products such as infusion therapy, oncology, vascular access, and tracheostomy products. The Infusion Systems segment offers large volume pumps, ambulatory infusion pumps, syringe infusion pumps, and IV medication safety software. The Vital Care segment encompasses products such as IV solutions, hemodynamic monitoring systems, general anesthesia and respiratory products, temperature management solutions, and regional anesthesia and pain management products.

ICU Medical's products are utilized in a wide range of healthcare settings, including acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities. The company's products are marketed and distributed globally through a network of owned and leased distribution centers, as well as through independent distributors.

The company has a strong reputation within the industry for providing high-quality, innovative products that meet the needs of healthcare professionals and patients. ICU Medical has a history of partnering with leading healthcare providers to develop and deliver products that enhance patient outcomes. The company's key competitors include other medical device companies such as B. Braun Medical, Hospira, and Smiths Medical.

ICU Medical's customers include a wide range of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities. Some of the company's largest customers include Medline, a leading provider of medical supplies and equipment, and Cardinal Health, a leading healthcare services company.

In terms of financial performance, ICU Medical has reported steady revenue growth over the past few years. The company's net sales have increased from $1.3 billion in 2018 to $1.6 billion in 2022, representing a compound annual growth rate of 5.5%. The company's net income has also increased over this period, from $143 million in 2018 to $234 million in 2022, representing a compound annual growth rate of 9.1%.

ICU Medical's product portfolio includes a range of brands and trade names. In the Consumables segment, the company offers products under the brands of IV House, Hyflex, and CLAVE. The Infusion Systems segment includes brands such as LifeCare PCA, LifeCare PCA+, and Plum 360. The Vital Care segment includes brands such as IV Solutions, Hemodynamic Monitoring, and Anesthesia and Respiratory.